Argolin® 0.5 mg Tablet: Each tablet contains cabergoline BP 0.5 mg.
Cabergoline, a dopamine D₂ receptor agonist which is used mainly to treat hyperprolactinemia and parkinsonism.
Mode of action:
Cabergoline is a potent dopaminergic agonist. It selectively binds with the D₂ receptors of pituitary gland. It inhibits the secretion of prolactin hormone.
Pharmacokinetics:
Cabergoline dissolves readily in the gastrointestinal tract. The compound was completely absorbed and extensively distributed in tissues, the most relevant localization of radioactivity being in the pineal gland and in the hypophysis. Plasma half life is about 62-91 hours and plasma protein binding is 41 to 42 %. The main route of excretions was fecal (72%); no more than 18% of the oral or intravenous dose was recovered in the urine.
Reduction of excessive prolactin levels, inhibition of lactation & parkinson’s diseases.
Age above 18: Initially 1 mg daily increased by increments of 0.5-1 mg at 7 or 14 day intervals; max. 3 mg daily.
Cabergoline may interact with the drug include: antipsychotic medications (Chlorpromazine, Haloperidol), antifungals (ketoconazole, itraconazole) can affect the removal of cabergoline from the body.
Over dosage:
Overdosage might be expected to produce nasal congestion, syncope, or hallucinations. Measures to support blood pressure should be taken if necessary.
USFDA Pregnancy Category B. As a precautionary measure, it is recommended that women seeking pregnancy should discontinue cabergoline 1 month before intended conception in order to prevent fetal exposure to the drug.
Initial doses higher than 1 mg may produce orthostatic hypotension. Care should be exercised when administering Cabergoline with other medications known to lower blood pressure.
Keep out of reach of children. Store in a dry place, below 25°C temperature and protected from light.